Hospira (HSP) Q2 2012 Earnings Call August 01, 2012 9:00 am ET Executives Karen King F. Michael Ball - Chief Executive Officer, Director and Member of Science, Technology & Quality Committee Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of R&D, Medical & Regulatory Analysts David H. Roman - Goldman Sachs Group Inc., Research Division Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division John M. Putnam - Capstone Investments, Research Division Ami Fadia - UBS Investment Bank, Research Division Matthew Taylor - Barclays Capital, Research Division Marshall Urist - Morgan Stanley, Research Division Gregory B. Gilbert - BofA Merrill Lynch, Research Division Shibani Malhotra - RBC Capital Markets, LLC, Research Division PresentationOperator
Welcome to Hospira's Second Quarter 2012 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference. Karen King Thank you. Good morning, everyone, and welcome to our second quarter 2012 conference call and webcast. Participating in today's call are Mike Ball, Chief Executive Officer, Hospira; Tom Werner, Senior Vice President, Finance and Chief Financial Officer; and Sumant Ramachandra, Senior Vice President and Chief Scientific Officer. We will be making some forward-looking statements today, which are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those indicated. A discussion of these factors is included in the Risk Factors and MD&A sections in Hospira's latest annual report on Form 10-K and subsequent Form 10-Qs on file with the SEC. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.